In response to Taiwan’s transition into a super-aged society, Sinphar and SynCore announced at their December 26th investor conference a strategy to align products with senior healthcare needs. The group is utilizing a "dual-track" strategy: leveraging high-repurchase health products for stable cash flow while advancing new drug development and functional products in partnership with Japan and ASEAN nations.

Performance and Outlook:

• Sinphar: Launched 16 new products in 2025 across pharmaceuticals, health supplements, and medical aesthetics; another 20 items are slated for 2026. Revenue for the first 11 months of 2025 reached NT$3.049 billion (+6.65% YoY), with a 9-month EPS of NT$1.39 (+18.8% YoY).
• Product Focus: General Manager Pai Yu-lang highlighted core demand for anti-aging, metabolic, joint, and immune-modulating products. Signature items like "Cogni-Memory" and "Activ-Heart (QH)" continue to outperform market averages.
• SynCore: General Manager Wang Hui-hung stated that the EndoTAG platform remains the core of their R&D, while the company scales up its health supplement business to accelerate growth momentum through 2026.

Resource: 杏輝、杏國 加速布局高齡市場